What Are Short-Chain Fatty Acids and Why Do They Matter?

Fiber gets talked about mostly in terms of what it does for you directly: bulk, regularity, feeling full. What actually happens to fiber once it leaves your small intestine is more interesting and gets less attention. Your body can’t digest most of it. Instead it travels to your colon, where trillions of bacteria ferment it and release a group of molecules called short-chain fatty acids. These molecules end up influencing your colon cells, your liver, your fat tissue, your immune system, and even your appetite. Here’s what’s actually going on.

What they actually are

Short-chain fatty acids (SCFAs) are fatty acids with fewer than six carbons, produced when gut bacteria ferment carbohydrates your own digestive enzymes can’t break down. Three of them dominate the picture: acetate (2 carbons), propionate (3 carbons), and butyrate (4 carbons). Together these three make up around 95% of the total SCFAs generated in the colon, typically in a ratio of roughly 3 parts acetate to 1 part propionate to 1 part butyrate [1,2].

Different bacteria specialize in different SCFAs. Bacteroides species mainly generate acetate and propionate through what’s called the succinate pathway. Butyrate is produced more selectively, largely by Firmicutes bacteria like Faecalibacterium prausnitzii and Roseburia species, which convert butyryl-CoA to butyrate using acetate as a co-substrate [2]. There’s also a good amount of cross-feeding going on: one bacterial species ferments fiber into an intermediate product like lactate or succinate, and a second species then converts that intermediate into a different SCFA. The community as a whole determines the output, not any single bacterial species acting alone [2].

The type of fiber matters too. Highly fermentable fibers like inulin and guar gum produce rapid spikes in circulating SCFAs, while more resistant forms of starch tend to favor butyrate specifically [2,3].

Where they actually go

Total SCFA concentration in the colon runs around 100 mM, which is a substantial amount [2]. But what’s in the colon and what reaches the rest of your body are two very different numbers. More than 90% of SCFAs get absorbed from the intestine, but they don’t all travel equally far. Butyrate is mostly used up locally by colonocytes (the cells lining your colon), providing an estimated 70% of their total energy needs [2,3]. Propionate travels to the liver and gets metabolized there, largely for gluconeogenesis. Acetate is the one that makes it furthest into general circulation, since it isn’t heavily metabolized by either the colon or the liver on its way through [2,3].

This matters because a lot of research measures SCFAs in stool, which mostly tells you what’s left over after colonocytes and the liver have already taken their share. Fecal SCFA levels are a fairly poor stand-in for what’s actually circulating or acting on distant tissues [1,4].

How they actually work

SCFAs act on the body through two main routes. The first is a family of G-protein-coupled receptors, mainly FFAR2 (also called GPR43) and FFAR3 (also called GPR41), along with a butyrate-specific receptor called GPR109A. These receptors sit on cells throughout the gut, immune system, fat tissue, liver, and nervous system, and when SCFAs bind to them they trigger signaling cascades that affect things like insulin secretion, inflammation, and appetite hormones [2,3].

The second route is more direct: SCFAs, especially butyrate, inhibit an enzyme class called histone deacetylases (HDACs). Blocking HDACs changes how tightly DNA is packaged around histones, which changes which genes get switched on or off. This is one of the main ways SCFAs affect immune cell behavior and gene expression without needing a receptor at all [2,3].

What they do once they get where they’re going

In the colon. Butyrate is the preferred fuel source for colonocytes and supports the tight junction proteins that hold the gut lining together. It also promotes mucus production and helps maintain the slightly acidic environment in the colon that keeps pathogens like E. coli and Salmonella from overgrowing [2,3].

In the liver. Propionate acts as a precursor for gluconeogenesis, while acetate contributes to fatty acid synthesis. Butyrate that reaches the liver in small amounts has been shown to activate AMPK and reduce fat accumulation in animal models of fatty liver disease [3,5].

In fat tissue. SCFAs suppress lipolysis by activating GPR43 on adipocytes, which lowers the release of free fatty acids into circulation. Acetate and propionate also promote the differentiation of new fat cells and, in some studies, the “browning” of white fat tissue toward a more metabolically active, heat-generating type [3,5].

In the pancreas. Propionate and butyrate stimulate insulin secretion from pancreatic beta cells both directly, through FFAR2 and FFAR3, and indirectly, by triggering the release of the gut hormone GLP-1 [3,5].

In the immune system. This is where SCFAs, particularly butyrate and propionate, do some of their most consistent work. They promote the differentiation of regulatory T cells, which help keep the immune system from overreacting, and they shift macrophages away from a pro-inflammatory state and toward an anti-inflammatory one. They also reduce production of inflammatory cytokines like TNF-alpha and IL-6 [2,3].

In appetite regulation. Acetate crosses the blood-brain barrier and acts on hypothalamic centers involved in satiety. Propionate and butyrate work more indirectly, triggering the release of PYY and GLP-1 from gut cells, both of which slow gastric emptying and reduce hunger [3,5]. A colon-targeted propionate supplement (delivered as inulin-propionate ester so it survives to the distal colon) has been shown in human trials to reduce energy intake and slow weight gain over several months [5].

The obesity paradox

Here’s where things get less tidy. You’d expect SCFAs, given their generally favorable effects on insulin sensitivity and inflammation, to be lower in people with obesity. Several studies show the opposite: fecal SCFA concentrations tend to run higher in individuals with obesity compared with lean controls [1,4]. A 2019 meta-analysis confirmed this pattern across multiple studies [4].

The likely explanation isn’t that SCFAs themselves are driving weight gain. It’s that fecal SCFA levels reflect a mix of production, absorption, and gut transit time, and these can all be altered in obesity. Elevated stool SCFAs might indicate increased fermentation combined with impaired colonic absorption, rather than a straightforward surplus [4]. This is backed up by intervention studies: when propionate or butyrate is delivered directly and absorption is controlled for, the outcomes tend to be favorable, improving insulin sensitivity and reducing appetite. It’s the observational, stool-based studies that produce the confusing picture [3,4]. The takeaway is that fecal SCFA concentration alone isn’t a reliable marker of whether SCFAs are “working” for you.

What actually raises SCFA production

The most consistent predictor across studies isn’t any single supplement, it’s fiber diversity. Diets with a wide range of plant fibers produce greater microbial diversity, and microbial diversity is tied to a healthier, more balanced SCFA profile [1,2]. Resistant starch (found in foods like cooled potatoes, legumes, and green bananas) is particularly associated with butyrate production specifically [5].

Mediterranean-style diets are consistently linked to higher fecal butyrate and propionate. Diets low in fermentable fiber, including low-FODMAP diets and ketogenic diets, tend to reduce total SCFA output, sometimes substantially [5]. High-protein diets with low fiber intake shift fermentation toward protein-derived byproducts in the distal colon, some of which (ammonia, certain amines) aren’t nearly as beneficial [5].

Direct oral or rectal SCFA supplementation has had a mixed track record in human trials. Butyrate enemas have shown some benefit in ulcerative colitis in certain studies but not others, and oral butyrate tablets for metabolic syndrome and type 2 diabetes have mostly failed to move the needle in randomized trials [2,3]. Part of the problem is delivery: SCFAs taken orally get absorbed early, well before reaching the colon where they’re needed. Newer approaches using enteric coatings or esterified compounds that release SCFAs specifically in the distal colon have shown more promise, but this remains an active area of research rather than a settled one [3,5].

Summary

Short-chain fatty acids are the direct output of your gut bacteria fermenting the fiber you eat, and they do far more than feed colon cells. Acetate, propionate, and butyrate each take different routes through the body, acting on the liver, fat tissue, pancreas, immune system, and brain through both receptor signaling and direct effects on gene expression. The research on disease associations is still catching up to the mechanisms, and the obesity paradox is a good reminder that stool measurements don’t tell the whole story. What’s clear across the research is that fiber diversity, more than any single food or supplement, is the most reliable way to keep this system working the way it’s supposed to.

Common Questions

What are the three main short-chain fatty acids?

Acetate, propionate, and butyrate. Together they make up roughly 95% of the short-chain fatty acids produced in the colon, usually in a ratio of about 3 parts acetate to 1 part propionate to 1 part butyrate.

Do short-chain fatty acids from yogurt or fermented foods do anything for you?

Small amounts are present in foods like yogurt and kimchi, but they get absorbed early in the digestive tract before reaching the colon, where most of the relevant biology happens. The short-chain fatty acids that matter for gut and metabolic health are the ones your own bacteria produce from fiber.

Is more butyrate always better?

Not necessarily. Butyrate's effect on cancer cells depends on concentration and cell type, and some trials of oral or rectal butyrate for conditions like ulcerative colitis have shown mixed or no benefit. The clearest and most consistent lever is fiber intake, not direct supplementation.

Why do people with obesity sometimes have higher fecal short-chain fatty acid levels?

This is one of the more counterintuitive findings in the research. It likely reflects impaired absorption or altered handling of short-chain fatty acids rather than short-chain fatty acids themselves causing weight gain. Stool levels are a poor stand-in for what's actually happening in the colon or bloodstream.

References